Christopher Mikson joins DLA Piper’s Litigation practice in Philadelphia and Washington, DC

Powered by LawFuel – January 23, 2020 – DLA Piper announced today that Christopher Mikson has joined the firm’s Litigation practice as a partner in Philadelphia and Washington, DC. 

Mikson, who is also a medical doctor and registered patent attorney, is an accomplished litigator who focuses on Food and Drug Administration regulatory matters; complex intellectual property, commercial and product liability litigation; and transactional due diligence and counseling in the healthcare and life sciences industries. 

“Chris’s unique training as a physician and lawyer makes him an invaluable addition to our growing life sciences practice,” said Loren Brown, global and US co-chair of DLA Piper’s Litigation practice. “He will greatly enhance both our regulatory and litigation capabilities in this key sector, and we are confident that our clients will value his advice and counsel immediately.” 

“Chris is a great fit for our platform, and he brings a skillset that adds depth to our capabilities in a number of areas, including FDA regulatory, product liability and intellectual property matters,” said Jeff Lehrer, managing partner of the firm’s Washington, DC, office. “We are thrilled to welcome him on board.”

Mikson, who joins from Mayer Brown, received his J.D. from Rutgers Law School and his B.A. from Rutgers College. He completed the Post-Baccalaureate Premedical Program at the University of Pennsylvania and received his M.D. from Jefferson Medical College.

Recent Posts on LawFuel

• BigLaw’s $50K Public Interest Stipend War: What It Really Means for Law Students
• Tiger Woods Arrested for DUI Again — What Florida Law Really Means for Him Now, and the Elite Lawyers Who Fight These Cases
• London Law Boss ‘Spitting Feathers’ Over Partners’ Sexual Harassment Pattern
  The boss of one of the London’s elite insurance law firms has taken the extraordinary step of personally overseeing misconduct complaints after rising allegations of bullying and sexual harassment among senior partners, shining a fresh, unflattering light on law firms’ ongoing struggle to clean up their cultures. Read more . .
• The $11 Million Club – BigLaw’s Partner Profit Machine Just Broke Another Record — And The 2026 Rankings Haven’t Even Dropped Yet
• Ropes & Gray Raids Latham & Watkins for Eight-Lawyer Paris PE/M&A Team
  In a bold lateral strike that underscores the fierce talent battle in Paris Big Law, Ropes & Gray has snapped up a high-powered eight-lawyer private equity and M&A group from rival Latham & Watkins. The move, confirmed by multiple sources including The Lawyer andLaw.com International, brings three partners — Denis Criton, (pictured) Gaëtan Gianasso, and Michael Colle
• Jay Lefkowitz, Kirkland Partner Who Represented Epstein, to Retire from Firm This Spring
• White & Case Hits $3.6bn — And It’s Just Getting Warmed Up
• $11 Million a Partner -The Big Law Pay Story That Makes Every Other Firm’s Numbers Look Modest
  Kirkland & Ellis just changed the frame for the entire industry If you write about lawyers for long enough, you make a quiet peace with the gap between your pay packet and theirs. This week, however, Kirkland & Ellis has made that gap feel almost cosmic. Equity partners at the world’s highest-grossing law firm averaged $11.1 million each for 2025 – a 20% increase on 2024. The major money figure places Kirkland’s partners in the earnings bracket of a top Premier League footballer, at roughly £22,500 a day. The firm simultaneously became the first law firm in history to break $10 billion in revenue, posting $10.56 billion for the year.
• The Private Equity Lawyer Who Will Run Weil Gotshal
  When Weil, Gotshal & Manges announced last week that Ramona Y. Nee will succeed Barry Wolf as Executive Partner from January 2027, the news landed with the quiet inevitability of a deal that everyone saw coming. Wolf, who has steered the firm for 16 years, called her “uniquely suited.” He was not exaggerating. For nearly a quarter-century Nee has been the quiet engine of Weil’s U.S. private equity practice and the beating heart of its Boston office. Now the firm is handing her the keys.